However, even among those participants who showed a
5% or greater BMD loss during DMPA treatment, none
continued to show a LS deficit of that magnitude three years
after stopping treatment; correspondingly, only 14% of these
participants continued to show a 5% or greater deficit at the
hip relative to baseline.
As all participants received